MassMutual Private Wealth & Trust FSB Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MassMutual Private Wealth & Trust FSB reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,069 shares of the biopharmaceutical company’s stock after selling 470 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Regeneron Pharmaceuticals were worth $2,898,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in REGN. Adirondack Trust Co. raised its position in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Trust Co. of Vermont raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares during the last quarter. Nvwm LLC lifted its position in Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

REGN stock opened at $681.58 on Tuesday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $738.60 and a two-hundred day moving average of $948.80. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on REGN shares. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.